State Street Corp Trims Holdings in Grifols, S.A. (NASDAQ:GRFS)

State Street Corp trimmed its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 12.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 700,791 shares of the biotechnology company’s stock after selling 96,973 shares during the quarter. State Street Corp’s holdings in Grifols were worth $6,223,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. acquired a new position in shares of Grifols during the second quarter worth about $1,235,000. Natixis Advisors LLC increased its position in Grifols by 116.0% during the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock worth $971,000 after purchasing an additional 82,723 shares during the period. Oppenheimer Asset Management Inc. increased its position in Grifols by 56.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 55,887 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 20,120 shares during the period. Black Creek Investment Management Inc. raised its stake in shares of Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares in the last quarter. Finally, Highland Peak Capital LLC acquired a new stake in shares of Grifols in the 2nd quarter valued at approximately $5,991,000.

Grifols Stock Down 2.5 %

GRFS stock opened at $7.65 on Friday. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company has a market cap of $5.26 billion, a P/E ratio of 7.89 and a beta of 0.43. The company’s 50-day moving average price is $8.27 and its 200 day moving average price is $8.12.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.